



08/27/97

262280-11902680

A/H

**Patent Case No.: PD0586Q**

ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application including a specification and claim(s) of:

Inventor(s): Julianne Berry, Joel A. Sequeira, and Imtiaz A. Chaudry

For: CHLOROFLUOROCARBON-FREE MOMETASONE FUROATE AEROSOL FORMULATIONS

Also enclosed are:

☐ \_\_\_\_\_ sheets of drawing(s).

☒ Declaration and Power of Attorney.

☐ A floppy disk, including the computer form of the Sequence Listing in the specification. The undersigned certifies that the computer form is equivalent in content to the Sequence Listing in the specification.

☐ \_\_\_\_\_

For	Number Filed (1)	Number Extra (2)	Rate	Fee
Basic Fee				\$770.00
Total Claims	16 - 20 =	(*)	x \$22.00	\$0
Independent Claims	3 - 3 =	(*)	x \$80.00	\$0
			<b>TOTAL FILING FEE</b>	<b>\$770.00</b>

\*If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

☒ The Commissioner is authorized to charge Deposit Account No. 19-0365 in the amount of the above Total Filing Fee. A duplicate of this sheet is enclosed.

☒ General Authorization. This paper constitutes a general authorization to the Commissioner, for any deficiency in the above Total Filing Fee and all fee requirements subsequent to the instant filing, to charge all fees for amendments, petitions, and any and all other papers to our Deposit Account 19-0365. This is not, however, an automatic authorization to charge our Deposit Account the Issue Fee.
"EXPRESS MAIL" label no.: TB863255789Date of Deposit: August 27, 1997

Robert A. Franks  
 Attorney/Agent for Applicant(s)  
 Reg. No.: 28605  
 SCHERING-PLOUGH CORPORATION  
 Patent Dept. K-6-1-1990  
 2000 Galloping Hill Road  
 Kenilworth, New Jersey 07033-0530  
 Telephone: (908) 298-2908  
 Facsimile: (908) 298-5388

Express Mail Label No.	<u>1B863255789</u>
Date of Deposit	<u>August 27, 1997</u>

5

PD0586Q

CHLOROFLUOROCARBON-FREE MOMETASONE  
FUROATE AEROSOL FORMULATIONS

10

INTRODUCTION TO THE INVENTION

15 The present invention pertains to aerosol  
formulations of drugs, such as those formulations  
suitable for use in pressurized aerosol metered dose  
inhalers. More specifically, the invention relates to  
aerosol formulations of the drug mometasone furoate  
with the propellant 1,1,1,2,3,3,3-Heptafluoropropane  
20 (HFC-227).

Aerosolized drugs have been used for many years to  
treat disorders of the respiratory system, and as a  
convenient means for the systemic introduction of  
various pharmaceutical agents into the body. The  
25 typical aerosol formulation in a metered dose inhaler  
for treating disorders such as asthma or rhinitis is a  
suspension of one or more drug substances in a fully  
halogenated (with chlorine and fluorine) lower alkyl  
compound propellant, further containing small amounts  
30 of surfactants and/or excipients which are usually  
soluble in the propellant.

Pharmaceutical agents administered by means of  
metered dose inhalers are usually bronchodilators or  
corticosteroids. The steroidal drugs which are  
35 currently available in this form for inhalation  
therapeutic uses in the United States include  
beclomethasone dipropionate (both for nasal and lower  
airway administration), budesonide (nasal and airway  
administration), dexamethasone sodium phosphate (nasal

08920611-082797

and airway administration), flunisolide (nasally administered), and triamcinolone acetonide (nasal and airway administration). Fluticasone propionate has also recently been approved for sale as a lower airway drug. Typical formulations contain chlorofluorocarbon propellants, the drug substance and ethanol, which is soluble in the propellant, and sometimes also contain a surfactant such as oleic acid for maintaining a stable suspension, lubrication of the metering valve and other functions.

However, certain of the steroids have significant solubility in ethanol. When there is insufficient ethanol present for maintaining a solution of these drugs in an aerosol canister, the normal temperature fluctuations encountered during storage and use can cause repeated solubility increases and decreases of a saturated solution. Each time the drug substance becomes less soluble, such as in a period of ambient temperature decrease, it tends to crystallize and, due to the typical slow rate of temperature change, grows into crystals much larger than those which can be properly dispensed - particularly when the drug is intended for delivery to the bronchia or lungs. In general, drug particle sizes from about 1 to about 5 micrometers are preferred for administration to the lower airway, with particles smaller than about 0.5 micrometers frequently being exhaled without complete deposition on tissues, while particles larger than about 10 micrometers can exhibit considerable deposition in the mouth and/or pharynx and therefore not reach the lower airway. Very large particles cannot pass through a metering valve and will not be reliably dispensed.

In the case of beclomethasone dipropionate, itself quite soluble in ethanol, an addition compound (sometimes called a "solvate" or "clathrate") can be formed from the compound and the chlorofluorocarbons or

08920611-082797  
262280-11902680

a fluorohydrocarbon; when this clathrate is formulated with a propellant, no particle size growth is noted.

With the implication of fully halogenated chlorofluorocarbon propellants in the environmentally harmful destruction of ozone in the upper atmosphere, the availability of these propellants has become quite restricted. This has encouraged development work toward formulations containing propellants having reduced upper atmospheric reactivity, such work particularly centering about the propellants 1,1,1,2-Tetrafluoroethane (HFC-134a) and HFC-227, these compounds having approximately the same physical properties as those of the older chlorofluorocarbons used for medicinal aerosols. Recent studies have imputed to HFC-134a an undesirable potential for surface water acidification, as it appears to form the environmentally very stable trifluoroacetic acid in the atmosphere.

It has been proposed in European Patent 0 553 298 B1 to formulate an aerosol with HFC-134a by simply including sufficient ethanol to maintain beclomethasone dipropionate in solution over at least the expected ambient temperature range. However, the presence of any ethanol is discouraged in many countries, due to the prevalence of alcoholism and the ease with which ethanol is systemically absorbed from lower airway tissues. Any products intended for use by children generally should have as low an ethanol content as possible.

International Patent Application WO 93/11745 discloses particle size-stable suspension aerosol formulations containing drug substances, a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, and a polar cosolvent such as an alcohol. No surfactants are said to be required.

International Patent Application WO 94/03153 reports that solvates of beclomethasone and HFC-134a

00920611-082797

can be used to produce stable suspensions in a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, in the substantial absence of solvating species such as alcohol.

5       The drug mometasone furoate would have advantages over the presently available corticosteroids for treating airway disorders. As reported in International Patent Application WO 95/20393, the drug has a very rapid onset of action and generally does not  
10       appear in detectable concentrations in the blood, following nasal or airway administration.

Unfortunately, this drug has a some solubility in ethanol and exhibits particle size increases during storage of suspension aerosol formulations prepared  
15       using large amounts of ethanol.

International Patent Applications WO 92/22287 and WO 92/22288 disclose aerosol formulations of mometasone furoate in the propellants HFC-134a and HFC-227, but do not address the problem of adverse particle size  
20       increases.

#### Summary of the Invention

In accordance with the invention, there is  
25       provided a particle size-stable pressurized aerosol suspension formulation of mometasone furoate, comprising the propellant HFC-227, about 1 to about 10 weight percent ethanol and mometasone furoate in concentrations at least about 1 percent of the ethanol  
30       concentration. The formulation can also contain a surfactant.

It has been discovered that the formulation of the invention does not exhibit significant particle size changes in the suspended drug. In addition, the  
35       densities of the solid and liquid phases are similar, giving a suspension which has a reduced tendency for particle settling; this results in a greatly

08920611-082797

facilitated re-dispersion into a uniform suspension, after the formulation has remained in an undisturbed condition for prolonged periods.

5                    Detailed Description of the Invention

          The invention provides pressurized aerosol formulations of the corticosteroid drug mometasone furoate, particularly formulations suitable for use in  
10    metered dose inhalers.

          Mometasone furoate is also known by the chemical name  $9\alpha,21$ -Dichloro- $11\beta,17$ -dihydroxy- $16\alpha$ -methylpregna-  
           $1,4$ -diene- $3,20$ -dione  $17$ -( $2$ -furoate), has the empirical  
          formula  $C_{27}H_{30}Cl_2O_6$  and has a molecular weight of 521.44.  
15    The drug is currently marketed in cream, ointment and  
          lotion formulations, for the treatment of various  
          dermatological conditions.

          In formulations of the present invention which are  
          suitable for treating lower respiratory system  
20    disorders such as asthma, at least a substantial  
          portion of the drug is present as suspended particles  
          having respirable sizes, e.g., about 0.5 to about 10  
          micrometers in their largest dimension. In inventive  
          formulations which are suitable for treating upper  
25    respiratory system disorders such as rhinitis, somewhat  
          larger drug particles may be permissible, but the  
          foregoing size range remains preferred.

          As with other drugs which have appreciable  
          solubility in ethanol, there is a tendency for  
30    mometasone furoate to exhibit crystal growth in  
          ethanol-containing formulations. However, the  
          inventors have discovered formulation parameters which  
          do not promote drug particle size growth. These  
          parameters also provide the advantage of minimizing the  
35    required ethanol concentrations, to reduce the  
          potential for unpleasant taste sensations and render

08920611-082797

the compositions more suitable for use by children and others with low alcohol tolerance.

It has been discovered that a certain minimum level of ethanol is needed to provide consistent and predictable delivery of the drug from a metered dose dispenser. This minimum level is about 1 weight percent of the total formulation, which results in a marginally acceptable drug delivery. Increased amounts of ethanol generally improve drug delivery characteristics.

However, for reasons previously discussed, and to prevent drug crystal growth in the formulation, it is necessary to limit the concentration of ethanol. Experimental data indicate that the ratio of the weight of mometasone furoate to the weight of ethanol is important in preventing particle size increases; in general, when the drug is present at 0.6 percent of the concentration of ethanol, immediate and severe adverse changes in crystal morphology and size are observed. This effect is not seen when the mometasone furoate is present at 1.3 percent of the ethanol concentration, leading to a conclusion that the drug must be present in concentrations at least about 1 percent of the ethanol concentration.

Limitations in the available metering valve delivery volumes (e.g., 25 to 100 microliters per actuation) and the amounts of drug substance required in a dose for treating a particular condition (generally about 10 to about 500 micrograms per valve actuation) will dictate the points within the foregoing ethanol parameters for a given formulation. Determination of such amounts is well within the skill of workers in this art.

A surfactant is frequently included in aerosol formulations, for purposes such as assisting with maintaining a stable suspension of the drug and lubricating the metering valve. The formulation of the

present invention does not require a surfactant for maintenance of ready dispersability (such as by moderate agitation immediately prior to use), as the drug forms loose flocculates in the propellant and does not exhibit a tendency to settle or compact. Upon undisturbed storage, the drug particles merely remain in their flocculated state.

However, surfactants can be incorporated, in small amounts as are customary in other aerosol suspensions, to ensure proper metering valve function. The commonly used oleic acid is suitable, at levels which will deliver up to about 50 micrograms of oleic acid per actuation of the valve. Of course, it is always desired to minimize the amounts of chemical substances in a medication dose, so the lowest concentrations which yield the desired effects are to be used. Other useful surfactants include, without limitation thereto, sorbitan trioleate, cetyl pyridinium chloride, soya lecithin, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (10) stearyl ether, polyoxyethylene (2) oleyl ether, polyoxyethylene-polyoxypropylene-ethylenediamine block copolymers, polyoxyethylene (20) sorbitan monostearate, polyoxyethylene-polyoxypropylene block copolymers, castor oil ethoxylate, and mixtures of any of the surfactants. It is generally preferred that the surfactant is soluble, at levels employed, in the alcohol-propellant solution. For any desired surfactant, simple experiments to measure drug delivery reproducibility can be employed to identify the optimum amount of surfactant for any given formulation and delivery system.

Formulations of the invention are made according to procedures customary in the art for other aerosol compositions. Typically, all components except the propellant are mixed and introduced into aerosol containers. The containers can then be chilled to

08920611-082797



temperatures below the boiling point of the propellant, and the required amount of the chilled propellant added before the metering valve is crimped onto the container. Alternatively, the containers can be fitted with a metering valve before being filled with propellant, and the required quantity of propellant will be introduced through the valve.

Certain aspects of the invention are further described in the following examples. In the examples, "percent" indicates weight percentage unless the context clearly indicates otherwise.

### Example 1

Following are examples of useful aerosol suspension formulations, according to the present invention. Ingredient amounts, in percent of mometasone furoate ("MF"), oleic acid ("Oleic"), ethanol ("EtOH") and HFC-227 ("Propellant"), are given.

	<u>Formulation</u>	<u>MF</u>	<u>Oleic</u>	<u>EtOH</u>	<u>Propellant</u>
	A	0.112	0.001	2.497	97.389
	B	0.028	0	1.750	98.222
	C	0.112	0.011	2.497	97.379
25	D	0.448	0.011	2.489	97.052
	E	0.112	0	2.497	97.390
	F	0.448	0.011	4.977	94.564
	G	0.224	0.011	2.494	97.270
	H	0.028	0.001	2.499	97.471
30	I	0.028	0.011	2.499	97.462

08920611-082797

Example 2

Experiments are performed to determine the effects on aerosol drug delivery characteristics from variable, low concentrations of ethanol. In these experiments, micronized mometasone furoate is incorporated into a "concentrate" suspension with the ethanol and, optionally, oleic acid. A required amount of the well-mixed concentrate for delivery of 120 doses is weighed into metal aerosol containers, a metering valve delivering 63 microliters per actuation (a volume containing 100 micrograms of mometasone furoate) is crimped onto the container and liquid HFC-227 propellant is weighed into the container through the valve. The concentration of mometasone furoate in the final formulation is 0.112%.

To test drug delivery from the containers, the weight of drug substance delivered by two actuations of the metering valve is measured, and divided by two to calculate the amount delivered in a single actuation. After a fixed number of "priming" actuations, this is done for the first two doses delivered from the container, two doses at the midpoint of doses to be delivered and two doses at the end of the intended capacity of the container. Tabulated below are average amounts recovered from multiple containers of each formulation, the formulation information identifying the amount of oleic acid delivered with each valve actuation.

1% Ethanol, 2.5  $\mu$ g Oleic Acid (6 containers)

Beginning	75.2 $\mu$ g
Midpoint	83.4 $\mu$ g
End	92.6 $\mu$ g

1.75% Ethanol, 10 µg Oleic Acid (6 containers)

Beginning	94.3 µg
Midpoint	96.4 µg
End	110 µg

2.5% Ethanol, 10 µg Oleic Acid (10 containers)

Beginning	104 µg
Midpoint	102 µg
End	106 µg

2.5% Ethanol, no Oleic Acid (10 containers)

Beginning	93.3 µg
Midpoint	98.8 µg
End	99.0 µg

The drug delivery from those containers having 1 percent ethanol could be marginally acceptable for a commercial product, while deliveries from all of the containers with higher alcohol level formulations would be acceptable. The general drug delivery standards for inhalation products intended to treat asthma are established by governmental agencies, such as the United States Food and Drug Administration.

Example 3

Experiments are conducted to determine the effects on drug particle size stability of variable ratios of drug to ethanol weights in aerosol formulations.

Formulations are prepared in glass containers, fitted with aerosol valves, from the following components, where amounts are in percent:

Formulation A

HFC-227	94.969
Ethanol	4.985
Mometasone Furoate	0.034

Oleic Acid 0.012  
Mometasone Furoate/Ethanol = 0.00674

Formulation B

5 HFC-227 97.457  
Ethanol 2.499  
Mometasone Furoate 0.032  
Oleic Acid 0.011  
Mometasone Furoate/Ethanol = 0.0130

Formulation C

10 HFC-227 97.366  
Ethanol 2.497  
Mometasone Furoate 0.127  
15 Oleic Acid 0.011  
Mometasone Furoate/Ethanol = 0.0508

Formulation D

20 HFC-227 97.188  
Ethanol 2.492  
Mometasone Furoate 0.308  
Oleic Acid 0.011  
Mometasone Furoate/Ethanol = 0.124

25 Each formulation is examined for evidence of  
crystal growth after preparation, by visually  
inspecting the container contents and by spraying a  
dose of the formulation onto a glass microscope slide,  
allowing the propellant to evaporate and visually  
30 inspecting particles on the slide with polarized light  
at 100X magnification. Formulation A shows extensive  
crystal morphology change, into elongated needle-like  
shapes, of which many have a maximum dimension  
appearing to be greater than about 30µm; the changes  
are visually apparent in the container without any  
35 magnification. Particles in each of the other  
formulations appear similar to those of the original

08926611 082797  
262880 11902680

micronized mometasone furoate, both in particle form and in size. Formulation A will not be suitable for the inhalation delivery of mometasone furoate.

5 The containers with Formulations B, C and D are subjected to a freeze/thaw temperature program, as follows: -20°C for 3 days, then room temperature for one day, then 50°C for 2 days, then -20°C for 4 days, then 50°C for 3 days, then -20°C for 3 days, then 50°C for 3 days, and finally room temperature for 1 day.

10 Upon repeating the microscopic examination, no temperature excursion-induced changes in particle form or size are observed in any of these formulations.

15 The foregoing descriptions of various embodiments of the invention are representative of various aspects of the invention, and are not intended to be exhaustive or limiting to the precise forms disclosed. Many modifications and variations undoubtedly will occur to those having skill in the art. It is intended that the scope of the invention shall be fully defined solely by the appended claims.

20

082280.1190280

WHAT IS CLAIMED IS:

1. An aerosol suspension formulation comprising 1,1,1,2,3,3,3-Heptafluoropropane, about 1 to about 10 weight percent ethanol and micronized mometasone furoate in concentrations at least about 1 percent of the ethanol concentration, the formulation optionally also containing a surfactant.

2. The aerosol suspension formulation of claim 1, comprising about 1 to about 5 weight percent ethanol.

3. The aerosol suspension formulation of claim 1, comprising about 2 to about 5 weight percent ethanol.

4. The aerosol suspension formulation of claim 1, which contains a surfactant.

5. The aerosol suspension formulation of claim 4, wherein the surfactant comprises oleic acid.

6. The aerosol suspension formulation of claim 1, which is contained in a metered dose container.

7. The aerosol suspension formulation of claim 1, which is contained in apparatus delivering a measured amount of about 10 to about 500 micrograms of mometasone furoate from a single actuating operation.

8. A method for treating allergic reactions in the respiratory tract, comprising administering by inhalation an aerosol suspension formulation comprising 1,1,1,2,3,3,3-Heptafluoropropane, about 1 to about 10 weight percent ethanol and micronized mometasone furoate in concentrations at least about 1 percent of the ethanol concentration, the formulation optionally also containing a surfactant.

20250611 092327

9. The method of claim 8, wherein the suspension comprises about 1 to about 5 weight percent ethanol.

10. The method of claim 8, wherein the suspension comprises about 2 to about 5 weight percent ethanol.

11. The method of claim 8, wherein the suspension contains a surfactant.

12. The method of claim 11, wherein the surfactant comprises oleic acid.

13. The method of claim 8, wherein the suspension is contained in a metered dose container.

14. The method of claim 8, wherein the suspension is contained in apparatus delivering a measured amount of about 10 to about 500 micrograms of mometasone furoate from a single actuating operation.

15. A metered dose inhaler which contains an aerosol suspension formulation comprising 1,1,1,2,3,3,3-Heptafluoropropane, about 1 to about 10 weight percent ethanol and micronized mometasone furoate in concentrations at least about 1 percent of the ethanol concentration, the formulation optionally also containing a surfactant.

16. The metered dose inhaler of claim 15, wherein about 10 to about 500 micrograms of mometasone furoate are delivered from a single actuating operation.

08920611.032797

ABSTRACT OF THE DISCLOSURE

The invention relates to suspension aerosol formulations which exhibit stable particle sizes, containing mometasone furoate, about 1 to about 10 weight percent ethanol and 1,1,1,2,3,3,3-Heptafluoropropane as the propellant. A surfactant, such as oleic acid, can also be included. These formulations are suitable for use in metered dose inhalers.

08920611-082797



DECLARATION AND POWER OF  
ATTORNEY FOR PATENT APPLICATION

Attorney's Docket No. PD0586Q

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"CHLOROFLUOROCARBON-FREE MOMETASONE FURATE AEROSOL  
FORMULATIONS"

the specification of which

☒ is attached hereto.

☐ was filed on \_\_\_\_\_ as Application Serial No. \_\_\_\_\_

and was amended on \_\_\_\_\_ (if applicable).

☐ was filed on \_\_\_\_\_ as PCT International Application No. \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s):

Priority Claimed

\_\_\_\_\_  
(Number)

\_\_\_\_\_  
(Country)

\_\_\_\_\_  
(Day/Month/Year Filed)

\_\_\_\_\_  
Yes or No

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

60/025,807

August 29, 1996

(Application Number)

(Filing Date)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

\_\_\_\_\_  
(Application Serial No.)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Status – patented, pending, abandoned)

08220611.082797

Power of Attorney: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in Patent and Trademark Office connected therewith. (List name and registration number.)

Carl W. Battle	Reg. No. 30731	Henry C. Jeanette	Reg. No. 30856
Edwin P. Ching	Reg. No. 34090	Susan Lee	Reg. No. 30653
Eric S. Dicker	Reg. No. 31699	Anita W. Magatti	Reg. No. 29825
Norman C. Dulak	Reg. No. 31608	John J. Maitner	Reg. No. 25636
Cynthia L. Foulke	Reg. No. 32364	Joseph T. Majka	Reg. No. 30570
Robert A. Franks	Reg. No. 28605	Arthur Mann	Reg. No. 35598
James M. Gould	Reg. No. 33702	Edward H. Mazer	Reg. No. 27573
Richard J. Grochala	Reg. No. 31518	James R. Nelson	Reg. No. 27929
Thomas D. Hoffman	Reg. No. 28221	Paul A. Thompson	Reg. No. 35385

Send Correspondence to:  Robert A. Franks Schering-Plough Corporation Patent Department, K-6-1, 1990 2000 Galloping Hill Road Kenilworth, New Jersey 07033-0530	Direct Telephone Calls to:  Name: Robert A. Franks Telephone No.: (908) 298-2908 Facsimile No.: (908) 298-5388
---	--

FULL NAME OF 1ST OR SOLE INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	Berry	Julianne	
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	Westfield	New Jersey	United States of America
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
	719 Castleman Drive	Westfield	New Jersey 07090/USA

FULL NAME OF 2ND JOINT INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	Sequeira	Joel	A.
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	Edison	New Jersey	United States of America
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
	6 Mary Ellen Drive	Edison	New Jersey 08820/USA

FULL NAME OF 3RD JOINT INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	Chaudry	Imtiaz	A.
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	North Caldwell	New Jersey	United States of America
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
	18 Rose Avenue	North Caldwell	New Jersey 07006/USA

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of First Inventor <i>Julianne Berry</i>	Signature of Second Inventor <i>Joel A. Sequeira</i>	Signature of Third Inventor <i>Imtiaz A. Chaudry</i>
Date 8/25/97	Date 8/25/97	Date 8/25/97

082797.082797